Neurogene (NGNE) Non-Current Deffered Revenue (2016 - 2018)
Neurogene (NGNE) posted Non-Current Deffered Revenue of $313000.0 for Q4 2018, down 6.01% on a QoQ basis from $333000.0 in Q3 2018, and down 30.91% year-over-year from $453000.0 in Q4 2017.
Neurogene (NGNE) Non-Current Deffered Revenue (2016 - 2018) Analysis & Trends
Neurogene's Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $313000.0 for Q4 2018.
- Quarterly Non-Current Deffered Revenue fell 30.91% year-over-year to $313000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $313000.0 (down 30.91% YoY) and the FY2018 annual result came in at $313000.0, down 30.91% from the prior year.
- Non-Current Deffered Revenue was $313000.0 for Q4 2018 at Neurogene, down from $333000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $518000.0 in Q1 2017 and bottomed at $25000.0 in Q1 2016.
- A 3-year average of $311666.7 and a median of $355000.0 in 2018 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2017 — Non-Current Deffered Revenue surged 1972.0% — and 2018, when it slumped 30.91%.
- Neurogene's Non-Current Deffered Revenue stood at $150000.0 in 2016, then jumped by 202.0% to $453000.0 in 2017, then slumped by 30.91% to $313000.0 in 2018.
- Business Quant data shows NGNE's Non-Current Deffered Revenue at $313000.0 in Q4 2018, $333000.0 in Q3 2018, and $377000.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Neurogene | 17.50 Mn | 17.50 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 313,000.00 |
| Sep 30, 2018 | 333,000.00 |
| Jun 30, 2018 | 377,000.00 |
| Mar 31, 2018 | 415,000.00 |
| Dec 31, 2017 | 453,000.00 |
| Sep 30, 2017 | 476,000.00 |
| Jun 30, 2017 | 508,000.00 |
| Mar 31, 2017 | 518,000.00 |
| Dec 31, 2016 | 150,000.00 |
| Sep 30, 2016 | 116,000.00 |
| Jun 30, 2016 | 56,000.00 |
| Mar 31, 2016 | 25,000.00 |